학술논문

Phase III LEAP-010 study: first-line pembrolizumab with or without lenvatinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Document Type
Journal
Source
JOURNAL OF CLINICAL ONCOLOGY; MAY 20 2020, 38 15, 2p. Supplement: S
Subject
Language
English
ISSN
15277755